Delcath Systems Inc. (NASDAQ: DCTH)
$7.96
-0.0050 ( -0.06% ) 156.4K
Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.
Market Data
Open
$7.96
Previous close
$7.96
Volume
156.4K
Market cap
$221.45M
Day range
$7.92 - $8.06
52 week range
$2.25 - $9.18
SEC Fillings
Form Type | Description | Pages | Date |
---|---|---|---|
8-k | 8K-related | 14 | Mar 26, 2024 |
10-k | Annual reports | 109 | Mar 26, 2024 |
4 | Insider transactions | 1 | Mar 20, 2024 |
4 | Insider transactions | 1 | Mar 20, 2024 |
4 | Insider transactions | 1 | Mar 20, 2024 |
4 | Insider transactions | 1 | Mar 20, 2024 |
3 | Insider transactions | 2 | Mar 20, 2024 |
4 | Insider transactions | 1 | Mar 19, 2024 |
4 | Insider transactions | 1 | Mar 19, 2024 |
8-k | 8K-related | 15 | Mar 19, 2024 |